GENEURO SA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0812 EUR | -32.05% |
|
-42.21% | -92.55% |
| Jul. 15 | GeNeuro to Apply for Debt Moratorium in Switzerland | MT |
| Jul. 15 | GeNeuro: a procedure to restructure debt | CF |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
GeNeuro SA specializes in the development of safe and effective treatments against neurological disorders and autoimmune diseases such as multiple sclerosis or type 1 diabetes by neutralizing causal factors encoded by HERVs, which represent 8% of human DNA. A new frontier pioneered by GeNeuro SA since 2006 and based on research by Institut Mérieux and INSERM.
Calendar
2024-09-29
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
2
Last Close Price
0.0812
EUR
Average target price
2.05
EUR
Spread / Average Target
+2,424.63%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -92.55% | 2.62M | |
| +22.15% | 46.56B | |
| +45.94% | 41.67B | |
| -2.37% | 41.16B | |
| +33.84% | 32.4B | |
| -6.35% | 28.1B | |
| +20.42% | 28.18B | |
| +48.83% | 14.52B | |
| +45.00% | 13.74B | |
| +0.06% | 12.17B |
- Stock Market
- Equities
- GNRO Stock
- News GeNeuro SA
- GeNeuro to Apply for Debt Moratorium in Switzerland
